- Home
- ACLX vs G Comparison
ACLX vs G Comparison
Compare ACLX & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLX | G |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | Bermuda |
| Employees | N/A | 140000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.8B |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ACLX | G |
|---|---|---|
| Price | $115.08 | $34.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $118.17 | $49.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 9.82 |
| EPS | N/A | ★ 3.13 |
| Revenue | $22,286,000.00 | ★ $2,279,438,000.00 |
| Revenue This Year | $342.39 | $9.20 |
| Revenue Next Year | $170.71 | $7.27 |
| P/E Ratio | ★ N/A | $10.99 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.86 | $33.14 |
| 52 Week High | $115.14 | $50.24 |
Technical Indicators
Market Signals| Indicator | ACLX | G |
|---|---|---|
| Relative Strength Index (RSI) | 79.86 | 37.68 |
| Support Level | $63.46 | N/A |
| Resistance Level | N/A | $38.03 |
| Average True Range (ATR) | 0.11 | 1.08 |
| MACD | -0.62 | -0.04 |
| Stochastic Oscillator | 84.28 | 22.05 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About G Genpact Limited
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.